ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib was the first TKI targeting BCR-ABL to obtain a marketing authorization (MA) in 2001 for Ph+ CML [2], followed by the development of the second-generation BCR-ABL inhibitors dasatinib, nilotinib, and bosutinib.